RHY rhythm biosciences limited

Sept '21 Deloitte's review of the National Bowel Cancer Screening Program, page-3

  1. 359 Posts.
    lightbulb Created with Sketch. 113
    @borano


    Review of Phase Four of the National Bowel Cancer Screening Program:

    "In any decision to transition to a new test type, it is important that the test is approved by the
    Therapeutic Goods Administration (as per the guidance in the NBCSP Quality Framework) and a
    cost-effectiveness analysis is performed using reliable estimates of test sensitivity and specificity,
    as compared with the current iFOBT."
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
5.7¢
Change
0.000(0.00%)
Mkt cap ! $16.19M
Open High Low Value Volume
5.7¢ 6.0¢ 5.7¢ $8.485K 144.9K

Buyers (Bids)

No. Vol. Price($)
1 2500 5.6¢
 

Sellers (Offers)

Price($) Vol. No.
5.9¢ 25000 1
View Market Depth
Last trade - 11.21am 16/07/2025 (20 minute delay) ?
RHY (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.